DelSiTech

Executive Summary

DelSiTech is a Finnish technology platform company developing long-acting injectable formulations based on its proprietary Silica Matrix technology. The platform enables sustained release of small molecules, peptides, and other therapeutic agents, with a focus on metabolic diseases and pain management. By transforming treatment landscapes through reduced dosing frequency and improved patient adherence, DelSiTech's lead assets target significant unmet needs. The company has demonstrated versatility across multiple drug classes, positioning itself as a potential partner for pharmaceutical companies seeking to extend patent life or improve drug profiles. DelSiTech's strategy centers on advancing its own pipeline while pursuing licensing and co-development opportunities. With a strong intellectual property portfolio and validated platform, the company is poised for milestones in both clinical and business development. Key upcoming catalysts include initiation of clinical trials for its lead candidate in metabolic disease, potential partnership agreements, and publication of preclinical data in peer-reviewed journals. The company's Turku, Finland base provides access to European biotech ecosystems and funding mechanisms.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead metabolic disease asset70% success
• H1 2027Strategic partnership or licensing deal with major pharma for Silica Matrix platform50% success
• Q3 2026Publication of preclinical efficacy data for pain candidate in a peer-reviewed journal80% success